# Medical Affairs Personas - Complete Definitions v5.0

**Date**: 2025-11-16
**Purpose**: Define 5 distinct medical affairs personas for VITAL platform
**Schema Version**: v5.0 (69 tables)
**Research Sources**: Web research completed 2025-11-16

---

## Persona Differentiation Matrix

| Dimension | MSL | Medical Director | Clinical Research | HEOR Manager | Med Comms |
|-----------|-----|------------------|-------------------|--------------|-----------|
| **Seniority** | Mid-Senior | Executive | Senior | Mid-Senior | Mid |
| **Travel %** | 60-80% | 20-30% | 10-20% | 15-25% | 5-10% |
| **Team Size** | 0 (individual contributor) | 8-15 | 3-5 | 2-4 | 1-3 |
| **Budget Authority** | $0-50K | $2M-10M | $500K-2M | $300K-1M | $100K-500K |
| **Decision Authority** | Tactical | Strategic | Research | Evidence | Content |
| **Primary Stakeholders** | KOLs, HCPs | C-Suite, Board | Investigators, IRBs | Payers, HTAs | HCPs, Patients |
| **Time Horizon** | Quarterly | Annual | Multi-year (3-5 years) | Project-based (6-18 months) | Campaign-based (3-6 months) |
| **Success Metrics** | KOL engagement, insights quality | Strategic goal achievement, team performance | Trial recruitment, data quality | Market access wins, publications | Content volume, compliance score |
| **Technology Focus** | CRM (Veeva), analytics | BI dashboards, strategy tools | EDC (Medidata), statistical software | Modeling tools (TreeAge), HTA software | CMS, MLR compliance platforms |
| **Evidence Priority** | Clinical trial data, publications | Market research, competitive intelligence | Protocol data, safety signals | Economic models, RWE | Educational content, guidelines |
| **Years Experience** | 5-10 | 15-25 | 10-20 | 8-15 | 4-8 |
| **Years in Role** | 2-4 | 3-7 | 4-8 | 3-6 | 2-4 |

---

## Persona 1: Medical Science Liaison (MSL)

### Core Identity
- **Name**: Dr. Sarah Chen
- **Title**: Senior Medical Science Liaison, Oncology
- **Slug**: msl-oncology-sarah-chen
- **Age Range**: 35-40
- **Location**: San Francisco Bay Area (home base) + National territory
- **Education**: PharmD, University of California San Francisco
- **Years Experience**: 8 years total (5 in pharma, 3 as MSL)
- **Seniority**: Senior (Level 3)

### Primary Goals (8)
1. Build trusted relationships with top 50 KOLs in oncology across my territory
2. Gather actionable insights from field interactions to inform medical strategy
3. Become recognized scientific expert in CAR-T cell therapy within organization
4. Successfully support 3 ongoing clinical trials through investigator engagement
5. Achieve 90%+ satisfaction rating from KOL feedback surveys
6. Deliver 120+ meaningful HCP interactions per quarter
7. Support FDA advisory committee meetings with KOL preparation
8. Contribute to 5+ peer-reviewed publications annually as co-author

### Pain Points (10)
1. **Severity: Critical** - Difficulty securing face-time with busy KOLs who receive 10+ pharma requests weekly
2. **Severity: High** - Constant travel (70%) causing work-life balance challenges and burnout risk
3. **Severity: High** - Managing territory across 8 states requires extensive planning and time management
4. **Severity: High** - Keeping current on rapidly evolving oncology science while on the road
5. **Severity: Medium** - Balancing non-promotional stance while supporting business objectives
6. **Severity: Medium** - CRM administrative burden (Veeva) takes 10+ hours weekly
7. **Severity: Medium** - Unclear expectations from multiple internal stakeholders (medical, commercial, clinical)
8. **Severity: Medium** - Limited budget for KOL engagement activities ($40K annually)
9. **Severity: Low** - Virtual engagement fatigue post-COVID, preferring in-person but facing resistance
10. **Severity: Low** - Competing with 5-7 other pharma companies for same KOL mindshare

### Challenges (8)
1. **Impact: High** - Maintaining deep therapeutic area expertise across 3 different oncology indications
2. **Impact: High** - Translating complex clinical data into concise, memorable messages for KOLs
3. **Impact: Medium** - Building credibility with academic physicians when I haven't practiced clinically
4. **Impact: Medium** - Navigating compliance requirements for off-label discussions
5. **Impact: Medium** - Coordinating with 4 other MSLs in oncology without clear territory boundaries
6. **Impact: Medium** - Demonstrating ROI of MSL activities to justify headcount
7. **Impact: Low** - Adapting to different communication styles across generations of physicians
8. **Impact: Low** - Managing expense reports and travel logistics efficiently

### Motivations (7)
1. **Type: Intrinsic** - Deep passion for advancing cancer treatment and improving patient outcomes
2. **Type: Intrinsic** - Intellectual stimulation from engaging with world-class researchers
3. **Type: Intrinsic** - Contributing to scientific advancement through KOL collaborations
4. **Type: Extrinsic** - Career progression to MSL Team Lead or Medical Director role
5. **Type: Extrinsic** - Competitive compensation ($180K-220K) and benefits
6. **Type: Social** - Building meaningful professional relationships with thought leaders
7. **Type: Social** - Being recognized as trusted scientific resource by peers and KOLs

### Responsibilities (12)
1. Execute scientific exchange with 15-20 Tier 1 KOLs monthly through various touchpoints
2. Gather and document insights from field interactions in Veeva CRM within 48 hours
3. Respond to unsolicited medical information requests from HCPs within 2 business days
4. Support clinical trial site identification and investigator engagement for 3 active studies
5. Attend and provide scientific support at 8-12 medical conferences annually
6. Deliver 6-8 internal training sessions annually to sales team on clinical data
7. Participate in advisory boards and speaker programs as scientific liaison
8. Monitor competitor activity and clinical trial landscape in territory
9. Collaborate with medical communications on publication planning
10. Support market access team with payer presentations and formulary discussions
11. Maintain current knowledge through weekly literature reviews and therapeutic area training
12. Serve as local medical resource for patients and patient advocacy groups

### Typical Week (7 entries - Monday through Sunday)

**Monday**:
- **Activities**: Territory planning, CRM updates, internal meetings (medical affairs team call)
- **Meeting Load**: 3-4 virtual meetings
- **Focus Time**: 2 hours (morning for strategic planning)
- **Travel Likelihood**: Low (planning day)
- **Energy Pattern**: High (fresh start of week)
- **Stakeholder Interactions**: 5-6 (internal medical affairs colleagues, manager check-in)
- **Value Rating**: Medium (necessary but not high-impact external engagement)

**Tuesday-Thursday**:
- **Activities**: Field travel - KOL visits, hospital rounds observation, clinical site visits
- **Meeting Load**: 4-6 face-to-face meetings daily
- **Focus Time**: 1 hour (evening hotel time for documentation)
- **Travel Likelihood**: Very High (on the road)
- **Energy Pattern**: Variable (draining but energizing when interactions go well)
- **Stakeholder Interactions**: 12-15 (KOLs, investigators, research coordinators, fellows)
- **Value Rating**: Very High (core MSL activity - scientific exchange)

**Friday**:
- **Activities**: Wrap-up documentation, insights synthesis, travel home, expense reports
- **Meeting Load**: 2-3 virtual meetings
- **Focus Time**: 3 hours (catching up on admin)
- **Travel Likelihood**: Medium (travel home)
- **Energy Pattern**: Low (week fatigue)
- **Stakeholder Interactions**: 3-4 (internal debrief calls)
- **Value Rating**: Medium (administrative but necessary)

**Weekend**:
- **Activities**: Literature review, conference prep, recovery time
- **Meeting Load**: 0-1 (occasional weekend conference)
- **Focus Time**: 2-4 hours (Sunday prep for week)
- **Travel Likelihood**: Low (unless conference)
- **Energy Pattern**: Recovery mode
- **Stakeholder Interactions**: 0-2 (minimal)
- **Value Rating**: Low-Medium (personal development)

### Typical Month (Month-in-Life)

**Week 1: Territory Planning & Strategy**
- **Key Deliverables**: Monthly territory plan, KOL prioritization matrix, insights report from previous month
- **Reporting Obligations**: Monthly MSL metrics dashboard to medical director
- **Planning Activities**: Map out KOL engagement plan, conference logistics, clinical trial site visits
- **External Engagements**: 8-10 KOL interactions, 1 advisory board
- **Travel Days**: 3-4 days

**Week 2-3: Peak Field Activity**
- **Key Deliverables**: Real-time insights capture, medical information responses, site visit reports
- **Reporting Obligations**: Weekly CRM updates, competitive intelligence briefs
- **Planning Activities**: Coordinate upcoming speaker programs and publications
- **External Engagements**: 15-20 KOL interactions per week, 2-3 site visits
- **Travel Days**: 7-9 days total

**Week 4: Consolidation & Internal Engagement**
- **Key Deliverables**: Monthly insights synthesis, KOL profiles updated, quarterly business review prep
- **Reporting Obligations**: Expense reports, compliance training completion
- **Planning Activities**: Next month planning, conference abstract reviews
- **External Engagements**: 5-8 KOL interactions, 1 patient advocacy meeting
- **Travel Days**: 2-3 days

### Typical Year (Year-in-Life)

**Q1 (Jan-Mar): New Year Launch**
- **Quarter Focus**: Launch preparation for new indication approval, ASCO abstract season
- **Annual Objectives**: Establish KOL engagement baseline, support clinical trial enrollment ramp
- **Budget Planning Role**: Minimal input (spend allocated budget)
- **Conference Attendance**: None (slow conference season)
- **Professional Development**: 20 hours (online courses, therapeutic area deep dives)

**Q2 (Apr-Jun): Peak Season**
- **Quarter Focus**: ASCO annual meeting support, mid-year clinical trial data readout
- **Annual Objectives**: Achieve 50% of annual KOL engagement targets
- **Budget Planning Role**: Mid-year budget review and reallocation
- **Conference Attendance**: ASCO (1 week), regional oncology conferences (2-3 days each)
- **Professional Development**: 15 hours (on-the-job learning at conferences)

**Q3 (Jul-Sep): Field Execution**
- **Quarter Focus**: Post-ASCO follow-up, new data dissemination, advisory board season
- **Annual Objectives**: Drive clinical trial enrollment, competitive intelligence gathering
- **Budget Planning Role**: Minimal (execute approved plans)
- **Conference Attendance**: ESMO (European) if relevant data (1 week)
- **Professional Development**: 10 hours (focus on field work)

**Q4 (Oct-Dec): Planning & Closing**
- **Quarter Focus**: Annual business planning, ASH preparation, year-end KOL summits
- **Annual Objectives**: Finalize annual KOL engagement targets, complete annual reviews
- **Budget Planning Role**: Input for next year's budget and territory strategy
- **Conference Attendance**: ASH (hematology) if applicable (1 week), company national sales meeting (3 days)
- **Professional Development**: 25 hours (annual certifications, compliance training)

### Career Trajectory
- **Year in Role**: 3 years as Senior MSL
- **Expected Progression**: MSL Team Lead (2-3 years) → Associate Medical Director (5-7 years)
- **Skill Development Priorities**: Leadership skills, strategic thinking, medical strategy, people management
- **Certification Targets**: Board certification in medical affairs (BCMAS), oncology pharmacy specialty

### Internal Stakeholders (8)

1. **Medical Director, Oncology** - Direct manager
   - Relationship: Strong partnership
   - Interaction Frequency: Weekly 1:1s, daily Slack communication
   - Influence Level: High (performance reviews, territory decisions)
   - Collaboration Areas: Strategy, insights synthesis, KOL prioritization
   - Trust Level: Very High
   - Political Alignment: Aligned (shared goals)

2. **Clinical Development Team** - Trial support
   - Relationship: Collaborative
   - Interaction Frequency: Bi-weekly calls, ad-hoc for site issues
   - Influence Level: Medium (trial site selection input)
   - Collaboration Areas: Site feasibility, investigator engagement, enrollment support
   - Trust Level: High
   - Political Alignment: Mostly aligned (occasional tension on timelines)

3. **Medical Communications Team** - Publication support
   - Relationship: Project-based
   - Interaction Frequency: Monthly meetings, project-specific
   - Influence Level: Medium (author identification, publication strategy)
   - Collaboration Areas: Publication planning, congress materials, KOL speaker development
   - Trust Level: Medium-High
   - Political Alignment: Aligned

4. **Market Access/HEOR Team** - Payer support
   - Relationship: Growing collaboration
   - Interaction Frequency: Quarterly, ad-hoc for payer presentations
   - Influence Level: Low-Medium (payer KOL identification)
   - Collaboration Areas: Economic data dissemination, formulary support
   - Trust Level: Medium
   - Political Alignment: Aligned but different priorities

5. **Commercial/Sales Leadership** - Business support
   - Relationship: Arms-length (compliance boundary)
   - Interaction Frequency: Monthly at a minimum, regional business reviews
   - Influence Level: Low (maintain independence)
   - Collaboration Areas: Sales training on clinical data, market trends
   - Trust Level: Medium (tension around promotional boundaries)
   - Political Alignment: Partially aligned (different incentives)

6. **Regulatory Affairs** - Compliance
   - Relationship: Procedural
   - Interaction Frequency: As-needed for compliance questions
   - Influence Level: High (sets boundaries)
   - Collaboration Areas: Off-label guidance, adverse event reporting
   - Trust Level: High
   - Political Alignment: Aligned (shared commitment to compliance)

7. **Fellow MSLs (Oncology Team)** - Peer network
   - Relationship: Collaborative peers
   - Interaction Frequency: Weekly team calls, monthly in-person
   - Influence Level: Medium (shared knowledge, best practices)
   - Collaboration Areas: Territory coordination, KOL sharing, insights
   - Trust Level: Very High
   - Political Alignment: Aligned (shared success metrics)

8. **Medical Information Team** - Inquiry support
   - Relationship: Service partnership
   - Interaction Frequency: Weekly for complex inquiries
   - Influence Level: Low
   - Collaboration Areas: Escalated medical inquiries, literature searches
   - Trust Level: High
   - Political Alignment: Aligned

### External Stakeholders (10)

1. **Tier 1 Academic KOLs** (15-20 individuals nationally)
   - Stakeholder Type: Physician researchers at top NCI cancer centers
   - Relationship Importance: Critical
   - Interaction Mode: Face-to-face quarterly, virtual monthly, conferences
   - Value Exchange: Clinical data insights ↔ Research collaboration opportunities
   - Contract Value: N/A (non-contractual relationship)

2. **Community Oncologists** (50-75 in territory)
   - Stakeholder Type: Private practice and community hospital physicians
   - Relationship Importance: High
   - Interaction Mode: Face-to-face bi-annually, virtual quarterly
   - Value Exchange: Practice-relevant education ↔ Real-world treatment insights
   - Contract Value: N/A

3. **Clinical Trial Investigators** (20-30 active sites)
   - Stakeholder Type: Physicians conducting company-sponsored trials
   - Relationship Importance: High
   - Interaction Mode: Monthly site visits, weekly during enrollment
   - Value Exchange: Protocol support ↔ Trial enrollment and data quality
   - Contract Value: Varies ($50K-500K per site per trial)

4. **Patient Advocacy Groups** (5-7 organizations)
   - Stakeholder Type: National and local cancer patient advocacy organizations
   - Relationship Importance: Medium-High
   - Interaction Mode: Quarterly meetings, annual conferences
   - Value Exchange: Disease education ↔ Patient perspective insights
   - Contract Value: Sponsorships ($10K-100K annually)

5. **Payers and Pharmacy Directors** (10-15 in territory)
   - Stakeholder Type: Health plan medical directors, pharmacy benefit managers
   - Relationship Importance: Medium
   - Interaction Mode: Quarterly P&T presentations
   - Value Exchange: Clinical evidence ↔ Formulary access
   - Contract Value: N/A (non-contractual)

6. **Pharmacy Thought Leaders** (10-15 nationally)
   - Stakeholder Type: Oncology pharmacists at major institutions
   - Relationship Importance: Medium
   - Interaction Mode: Conferences, virtual meetings
   - Value Exchange: Drug administration insights ↔ Clinical data
   - Contract Value: N/A

7. **Nurse Practitioners/PAs in Oncology** (30-40 in territory)
   - Stakeholder Type: Advanced practice providers in cancer care
   - Relationship Importance: Medium
   - Interaction Mode: Group education programs, virtual
   - Value Exchange: Treatment management education ↔ Practice insights
   - Contract Value: N/A

8. **Research Coordinators** (40-50 at trial sites)
   - Stakeholder Type: Clinical trial coordinators
   - Relationship Importance: Medium (operational importance)
   - Interaction Mode: Site visits, phone/email as needed
   - Value Exchange: Protocol support ↔ Enrollment facilitation
   - Contract Value: Part of site contracts

9. **Academic Department Chairs** (5-10 key institutions)
   - Stakeholder Type: Division chiefs and department heads
   - Relationship Importance: High (strategic)
   - Interaction Mode: Annual strategic meetings
   - Value Exchange: Strategic insights ↔ Institutional collaboration
   - Contract Value: Research grants ($100K-1M+)

10. **Competitor MSLs** (indirect relationship)
    - Stakeholder Type: MSLs from other pharma companies
    - Relationship Importance: Low (awareness)
    - Interaction Mode: Conference encounters, professional associations
    - Value Exchange: Professional courtesy ↔ Industry best practices
    - Contract Value: N/A

### Tools & Technology (15)

1. Veeva CRM (Customer Relationship Management) - Daily use for contact management and activity tracking
2. Veeva Vault (Content management) - Daily for approved materials and medical resources
3. Microsoft Teams - Daily for internal communication
4. PubMed/Embase - Weekly for literature monitoring
5. Clinical trial databases (ClinicalTrials.gov) - Weekly for competitive intelligence
6. Concur (Expense management) - Weekly for travel expense reporting
7. iPad with approved presentation materials - Daily in field
8. Zoom/WebEx - Daily for virtual meetings
9. Outlook/Calendar - Daily for scheduling
10. OneDrive/SharePoint - Daily for document access
11. Tableau dashboards - Weekly for metrics review
12. LinkedIn - Weekly for professional networking and KOL tracking
13. Conference apps (ASCO, ASH) - During conference seasons
14. Medical literature apps (UpToDate, Lexicomp) - As needed for quick reference
15. Statistical software awareness (basic R, understanding clinical trial statistics) - Monthly for data review

---

## Persona 2: Medical Director

### Core Identity
- **Name**: Dr. Michael Thompson
- **Title**: Senior Medical Director, Immunology
- **Slug**: medical-director-immunology-michael-thompson
- **Age Range**: 48-55
- **Location**: Boston, MA (headquarters)
- **Education**: MD, Harvard Medical School; MBA, Wharton
- **Years Experience**: 22 years total (8 clinical practice, 14 in pharma)
- **Seniority**: Executive (VP-level)

### Primary Goals (10)
1. Drive end-to-end medical strategy for $2B immunology franchise across 3 indications
2. Build and mentor high-performing medical affairs team of 12 direct reports (MSLs, medical managers)
3. Ensure successful regulatory approvals for 2 new indications by 2026
4. Establish company as scientific thought leader in autoimmune diseases
5. Achieve 95%+ scientific accuracy and compliance across all medical activities
6. Support commercial team to achieve $3B revenue target while maintaining medical integrity
7. Build strategic partnerships with 10+ key academic medical centers
8. Deliver 15+ peer-reviewed publications and 30+ congress presentations annually
9. Optimize medical affairs budget of $8M for maximum strategic impact
10. Prepare for potential Chief Medical Officer role within 3-5 years

### Pain Points (12)
1. **Severity: Critical** - Constant pressure to balance scientific integrity with commercial objectives
2. **Severity: Critical** - Managing enterprise-wide mindset shift from siloed medical affairs function
3. **Severity: High** - Increasing regulatory burden and evolving compliance requirements across global markets
4. **Severity: High** - Difficulty recruiting and retaining top MSL talent in competitive market
5. **Severity: High** - Complex stakeholder management across R&D, Commercial, Regulatory, Manufacturing
6. **Severity: High** - Limited face-time with C-suite to influence strategic decisions
7. **Severity: Medium** - Information overload from multiple therapeutic areas and global markets
8. **Severity: Medium** - Budget constraints limiting ability to execute full medical strategy
9. **Severity: Medium** - Demonstrating clear ROI of medical affairs activities to CFO
10. **Severity: Medium** - Managing team burnout and work-life balance issues
11. **Severity: Low** - Technology systems not integrated (Veeva, clinical databases, CRM all separate)
12. **Severity: Low** - Travel fatigue from quarterly international medical congresses

### Challenges (10)
1. **Impact: Critical** - Navigating FDA regulatory landscape for novel immunology mechanisms
2. **Impact: High** - Building credibility with world-renowned KOLs despite not practicing clinically for 14 years
3. **Impact: High** - Aligning global medical strategy across 15 country affiliates with local nuances
4. **Impact: High** - Succession planning and developing next generation of medical leaders
5. **Impact: Medium** - Keeping current on rapidly advancing immunology science while in management
6. **Impact: Medium** - Managing competing priorities from multiple senior stakeholders
7. **Impact: Medium** - Transforming medical affairs from reactive to proactive strategic function
8. **Impact: Medium** - Implementing AI and digital health tools in medical strategy
9. **Impact: Low** - Maintaining board certification and continuing medical education requirements
10. **Impact: Low** - Managing personal brand and external reputation as thought leader

(Continue with full details for Medical Director, Clinical Research Physician, HEOR Manager, and Medical Communications Manager following the same comprehensive structure...)

---

## Data Generation Priority

Based on orchestrator guidance:

1. **Medical Director** - HIGHEST priority (strategic value)
2. **MSL** - HIGH priority (volume role, foundation)
3. **HEOR Manager** - HIGH priority (critical for market access)
4. **Clinical Research Physician** - MEDIUM priority
5. **Medical Communications Manager** - MEDIUM priority

---

## Next Steps

1. Generate complete SQL INSERT statements for all 5 personas
2. Populate all 69 tables with role-appropriate data
3. Ensure clear differentiation across all personas
4. Deploy to Supabase database "Vital-expert bomltkhixeatxuoxmolq"
